Key result
Novel biomarkers show promise as diagnostic and prognostic tools across stroke onset, pathogenesis, and recovery.
Answers are grounded in this paper and cite their sources.
Since the increasing update of the biomolecular scientific literature, biomarkers in stroke have reached an outstanding and remarkable revision in the very recent years. Besides the diagnostic and prognostic role of some inflammatory markers, many further molecules and biological factors have been added to the list, including tissue derived cytokines, growth factor-like molecules, hormones, and microRNAs. The literatures on brain derived growth factor and other neuroimmune mediators, bone-skeletal muscle biomarkers, cellular and immunity biomarkers, and the role of microRNAs in stroke recovery were reviewed. To date, biomarkers represent a possible challenge in the diagnostic and prognostic evaluation of stroke onset, pathogenesis, and recovery. Many molecules are still under investigation and may become promising and encouraging biomarkers. Experimental and clinical research should increase this list and promote new discoveries in this field, to improve stroke diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Gandolfi et al. (2017) conducted a review in Stroke. Biomarkers was evaluated. A review of emerging biomarkers indicates that cytokines, growth factors, hormones, and microRNAs may serve as promising diagnostic and prognostic tools for stroke onset, pathogenesis, and recovery.
Synapse has enriched 10 related papers. Consider them for comparative context: